En undersøgelse til evaluering af effektivitet og sikkerhed af intravenøs ACU193 hos deltagere med tidlig Alzheimers sygdom (ALTITUDE-AD) (ALTITUDE-AD)
Et fase 2/3 dobbeltblindt, randomiseret, placebokontrolleret adaptivt designforsøg for at evaluere effektiviteten og sikkerheden af intravenøs ACU193 ved tidlig Alzheimers sygdom
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
British Columbia
-
Kelowna, British Columbia, Canada
- Okanagan Clinical Trials
-
-
Ontario
-
Ottawa, Ontario, Canada
- Hippocampe d/b/a Ottawa Memory Clinic
-
Toronto, Ontario, Canada
- Toronto Memory Program (TMP) (Neurology Research Inc.)
-
-
Quebec
-
Greenfield Park, Quebec, Canada
- MoCA Research and Innovations
-
-
-
-
-
Bristol, Det Forenede Kongerige
- Re:Cognition Health - Bristol
-
-
Greater London
-
London, Greater London, Det Forenede Kongerige
- Re:Cognition Health - London
-
London, Greater London, Det Forenede Kongerige
- St. Pancras Clinical Research Ltd.
-
-
Hampshire
-
Winchester, Hampshire, Det Forenede Kongerige
- Re:Cognition Health - Winchester
-
-
Lanarkshire
-
Motherwell, Lanarkshire, Det Forenede Kongerige
- Neuroclin Glasgow
-
-
Lancashire
-
Preston, Lancashire, Det Forenede Kongerige
- Panthera Bio-Partners - Preston
-
-
Surrey
-
Guildford, Surrey, Det Forenede Kongerige
- Re:Cognition Health - Guildford
-
-
Yorkshire
-
Sheffield, Yorkshire, Det Forenede Kongerige
- Panthera Biopartners - Sheffield
-
-
-
-
California
-
Carlsbad, California, Forenede Stater, 92011-4219
- The Neurology Center of Southern California - Carlsbad
-
Fullerton, California, Forenede Stater, 92835
- Neurology Center of North Orange County
-
Irvine, California, Forenede Stater, 92614
- Irvine Medical Research
-
Long Beach, California, Forenede Stater, 90804
- Healthy Brain Research
-
Santa Ana, California, Forenede Stater, 92705
- Syrentis Clinical Research
-
Sherman Oaks, California, Forenede Stater, 91403-2131
- CenExel - California Neuroscience Research Medical Group, Inc (CNR)
-
-
Connecticut
-
Norwalk, Connecticut, Forenede Stater, 06851-4903
- Research Center for Clinical Studies, LLC
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 22031
- Re:Cognition Health - Fairfax
-
-
Florida
-
Atlantis, Florida, Forenede Stater, 33462
- JEM Research Institute
-
Bradenton, Florida, Forenede Stater, 34205
- Bradenton Research Center
-
Coral Gables, Florida, Forenede Stater, 33135
- Gil Fernandez-Yera, MD, PA
-
Delray Beach, Florida, Forenede Stater, 33445
- Brain Matters Research
-
Homestead, Florida, Forenede Stater, 33032
- Coral Clinical Research
-
Lady Lake, Florida, Forenede Stater, 32159
- K2 Medical Research - Villages
-
Miami, Florida, Forenede Stater, 33126
- Finlay Medical Research
-
Naples, Florida, Forenede Stater, 34105-8522
- Aqualane Clinical Research
-
Ocala, Florida, Forenede Stater, 34470
- Ocala Health - Family Care Specialists - Ocala I
-
Port Orange, Florida, Forenede Stater, 32127
- Progressive Medical Research
-
Stuart, Florida, Forenede Stater, 34997
- Alzheimer's Research and Treatment Center - Stuart
-
Tampa, Florida, Forenede Stater, 33607
- K2 Medical Research - Tampa
-
The Villages, Florida, Forenede Stater, 32162
- Charter Research - Lady Lake
-
Wellington, Florida, Forenede Stater, 33414
- Alzheimers Research and Treatment Center - Wellington
-
Winter Park, Florida, Forenede Stater, 32789
- Conquest Research
-
Winter Park, Florida, Forenede Stater, 32792
- Charter Research - Winter Park
-
-
Georgia
-
Columbus, Georgia, Forenede Stater, 31909
- Columbus Memory Center
-
Decatur, Georgia, Forenede Stater, 30030
- CenExel - iResearch Atlanta
-
-
Illinois
-
Northbrook, Illinois, Forenede Stater, 60640
- Office of Jeffrey S. Ross, MD
-
-
Massachusetts
-
Newton, Massachusetts, Forenede Stater, 02459
- Boston Center for Memory
-
-
Mississippi
-
Hattiesburg, Mississippi, Forenede Stater, 39401-7246
- Hattiesburg Clinic - Memory Center
-
-
New Hampshire
-
Portsmouth, New Hampshire, Forenede Stater, 03801
- ActivMed Practices and Research
-
-
New Jersey
-
Springfield, New Jersey, Forenede Stater, 07081
- The Cognitive and Research Center of New Jersey
-
Toms River, New Jersey, Forenede Stater, 08755
- CenExel - Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Neurological Associates of Albany
-
-
North Carolina
-
Matthews, North Carolina, Forenede Stater, 28105
- AMC Research
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- Summit Research Network
-
-
Pennsylvania
-
Abington, Pennsylvania, Forenede Stater, 19001
- Abington Neurological Associates
-
Norristown, Pennsylvania, Forenede Stater, 19462
- Keystone Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, Forenede Stater, 02914
- Rhode Island Mood and Memory
-
-
Tennessee
-
Cordova, Tennessee, Forenede Stater, 38018
- Neurology Clinic. P.C
-
Knoxville, Tennessee, Forenede Stater, 37920-1511
- The Alliance for Multispecialty Research LLC (AMR)
-
-
Texas
-
Austin, Texas, Forenede Stater, 78757
- Senior Adult Specialty Research
-
Beaumont, Texas, Forenede Stater, 77702
- Gadolin Research, LLC
-
Dallas, Texas, Forenede Stater, 75231
- Kerwin Medical Center
-
-
-
-
-
Barcelona, Spanien
- Fundacio ACE
-
Donostia / San Sebastian, Spanien
- Policlínica Gipuzkoa
-
Getxo, Spanien
- Cae Oroitu
-
Madrid, Spanien
- Hospital Ruber
-
Seville, Spanien
- Hospital Victoria Eugenia
-
Valencia, Spanien
- Hospital Universitari i Politècnic La Fe
-
-
Barcelona
-
Sant Cugat del Vallès, Barcelona, Spanien
- Hospital Universitari General de catalunya
-
-
Zaragoza
-
Cuarte de Huerva, Zaragoza, Spanien
- Fundacion Neuropolis - Hospital Viamed Montecanal
-
-
-
-
-
Berlin, Tyskland
- Charité - Universitaetsmedizin Berlin
-
Cologne, Tyskland
- University Hospital of Cologne
-
Mannheim, Tyskland
- Zentralinstitut für seelische Gesundheit
-
Munich, Tyskland
- Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening
-
Must consent to apolipoprotein E4 (APOE4) genotype status assessment
-
Must meet all of the following criteria
- National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
- Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
- Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
- Evidence of cerebral amyloid accumulation by either PET scan or CSF
-
If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study
-
Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)
-
Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception
Exclusion Criteria:
-
Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI
-
MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis
-
History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease
-
Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study
-
Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)
-
Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study
-
Suicide risk, as determined by meeting any of the following criteria:
- Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
- Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
- Significant risk of suicide, as judged by the site investigator
-
Conditions that may affect cognitive assessments during the study
-
Alcohol use disorder and/or substance use disorder within the last five years
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period. |
Intravenous sabirnetug |
|
Eksperimentel: DBT Period: sabirnetug 50 mg/kg
Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period. |
Intravenous sabirnetug |
|
Placebo komparator: DBT Period: Placebo
Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period. |
Intravenous Placebo |
|
Eksperimentel: Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period. |
Intravenous sabirnetug |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
Tidsramme: Baseline up to Week 80
|
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance. |
Baseline up to Week 80
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antal deltagere med behandlingsrelaterede bivirkninger (TEAE'er)
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Antal deltagere med alvorlige bivirkninger (SAE) og bivirkninger af særlig interesse (AESI)
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Antal deltagere, der stopper eller trækker sig på grund af TEAE
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Antal deltagere med antistof antistoffer (ADA) og neutraliserende antistoffer
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Antal deltagere med amyloid-relateret billeddiagnostik med ødem/effusioner (ARIA-E) og ARIA med blødning/hæmosiderin-aflejring (ARIA-H) målt ved magnetisk resonansbilleddannelse (MRI)
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
CSF-koncentrationer af ACU193 i en undergruppe af deltagere
Tidsramme: Op til uge 76
|
Op til uge 76
|
|
|
Ændring fra baseline i amyloid plakbelastning eller aflejring målt ved positronemissionstomografi (PET) i centiloider
Tidsramme: Baseline op til uge 76
|
Baseline op til uge 76
|
|
|
Ændring fra baseline i volumetrisk magnetisk resonansbilleddannelse (vMRI) af helhjernevolumen, ventrikulærvolumen og volumen af udvalgte områder af interesse
Tidsramme: Baseline op til uge 76
|
Baseline op til uge 76
|
|
|
Ændring fra baseline i CSF-koncentrationer af amyloid, Tau og andre neurodegenerative biomarkører
Tidsramme: Baseline op til uge 76
|
Baseline op til uge 76
|
|
|
Ændring fra baseline i CSF-koncentrationer af amyloid, Tau og andre neurodegenerative biomarkører i en undergruppe af deltagere
Tidsramme: Baseline op til uge 76
|
Baseline op til uge 76
|
|
|
Ændring fra baseline i blodkoncentrationer af amyloid, Tau og andre neurodegenerative biomarkører
Tidsramme: Baseline op til uge 76
|
Baseline op til uge 76
|
|
|
Effekt af sabirnetug på klinisk progression sammenlignet med placebo vurderet ved brug af tidsbesparet analyse målt ved iADRS
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Effekt af sabirnetug på klinisk progression sammenlignet med placebo vurderet ved brug af tidsbesparet analyse målt ved ADCS-iADL
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Effekt af sabirnetug på klinisk progression sammenlignet med placebo vurderet ved brug af tidsbesparet analyse målt ved ADAS-Cog13
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Effekt af sabirnetug på klinisk progression sammenlignet med placebo vurderet ved hjælp af tidsbesparet analyse målt ved CDR-SB
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Effekt af sabirnetug på klinisk progression sammenlignet med placebo vurderet ved hjælp af tidsbesparet analyse målt ved MMSE
Tidsramme: Baseline op til uge 80
|
Baseline op til uge 80
|
|
|
Serum Koncentration af sabirnetug
Tidsramme: Før dosis og flere tidspunkter efter dosis op til 80 uger
|
Før dosis og flere tidspunkter efter dosis op til 80 uger
|
|
|
Koncentration af sabirnetug i cerebrospinalvæske (CSF)
Tidsramme: Op til uge 76
|
Op til uge 76
|
|
|
Målengagement vurderet ved måling af sabirnetug-amyloid-β oligomer (AβO) kompleks i CSF
Tidsramme: Op til uge 76
|
Op til uge 76
|
|
|
Change from Baseline in ADCS-iADL Score
Tidsramme: Baseline up to Week 80
|
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment. |
Baseline up to Week 80
|
|
Change from Baseline in ADAS-Cog13 Score
Tidsramme: Baseline up to Week 80
|
ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. |
Baseline up to Week 80
|
|
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Tidsramme: Baseline up to Week 80
|
The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Mini-Mental State Examination (MMSE)
Tidsramme: Baseline up to Week 80
|
MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
Tidsramme: Baseline up to Week 80
|
The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life. |
Baseline up to Week 80
|
|
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
Tidsramme: Baseline up to Week 80
|
NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress. |
Baseline up to Week 80
|
|
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
Tidsramme: Baseline up to Week 80
|
EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine. |
Baseline up to Week 80
|
|
Change from Baseline in Resource Utilization in Dementia (RUD)
Tidsramme: Baseline up to Week 80
|
The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies. |
Baseline up to Week 80
|
|
Change from Baseline in Zarit Burden Interview (ZBI)
Tidsramme: Baseline up to Week 80
|
ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden. |
Baseline up to Week 80
|
|
Percentage of Participants with No Clinical Progression at One Year
Tidsramme: Baseline up to Week 80
|
No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Baseline up to Week 80
|
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
Baseline up to Week 80
|
|
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
Tidsramme: Baseline up to 80 weeks
|
Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study. |
Baseline up to 80 weeks
|
|
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
Tidsramme: Up to 80 weeks
|
Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group. |
Up to 80 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Psykiske lidelser
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Kognitionsforstyrrelser
- Demens
- Tauopatier
- Neurodegenerative sygdomme
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Kognitiv dysfunktion
- Alzheimers sygdom
- Hukommelsesforstyrrelser
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ACU193-201
- 2023-509807-34-00 (Registry Identifier: EU CT Number)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .